Alterity Therapeutics Limited (ATHE)
NASDAQ: ATHE · Real-Time Price · USD
2.200
+0.100 (4.76%)
Dec 20, 2024, 4:00 PM EST - Market closed
Alterity Therapeutics Revenue
In the fiscal year ending June 30, 2024, Alterity Therapeutics had annual revenue of 4.02M AUD with 2.63% growth. Alterity Therapeutics had revenue of 2.12M in the half year ending June 30, 2024, a decrease of -23.36%.
Revenue (ttm)
4.02M AUD
Revenue Growth
+2.63%
P/S Ratio
n/a
Revenue / Employee
401,929 AUD
Employees
10
Market Cap
18.30M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Flora Growth | 64.15M |
BioLineRx | 21.99M |
CervoMed | 10.07M |
Bolt Biotherapeutics | 9.78M |
Palatin Technologies | 2.38M |
Cyclo Therapeutics | 870.73K |
ATHE News
- 17 days ago - Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy - GlobeNewsWire
- 4 weeks ago - Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary - GlobeNewsWire
- 5 weeks ago - Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium - GlobeNewsWire
- 6 weeks ago - Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434 - GlobeNewsWire
- 7 weeks ago - Appendix 4C – Q1 FY25 Quarterly Cash Flow Report - GlobeNewsWire
- 2 months ago - Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024 - GlobeNewsWire
- 2 months ago - Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting - GlobeNewsWire
- 2 months ago - Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders® - GlobeNewsWire